Stocktoria

PROKIDNEY CORP. PROK

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-06-30

PROKIDNEY CORP. statistics & valuation

Market cap$552.8M
Net margin-7725.2%
FCF margin-15152.6%
Return on capital-54.1%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Net margin (%)
-80507.90% -7725.20% 20212022202320242025
Gross margin (%)
20212022202320242025
Operating margin (%)
-241678.90% -18477.80% 20212022202320242025
Return on equity (%)
-204.90% 20212022202320242025
Shares outstanding
61.5M 20212022202320242025
Net debt ($)
20212022202320242025
Share buybacks ($)
20212022202320242025
Return on assets (%)
-136.80% -8.40% -13.90% -20.60% 20212022202320242025
Free cash flow margin (%)
-205078.90% -15152.60% 20212022202320242025
Debt / equity (×)
20212022202320242025
EPS ($)
-$0.23 20212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021
Operating margin-18477.8%-241678.9%———
Net margin-7725.2%-80507.9%———
FCF margin-15152.6%-205078.9%———
Return on assets-20.6%-13.9%-8.4%—-136.8%
Return on equity6.8%6.1%3.2%—-204.9%
Current ratio9.1310.9314.9446.422.21

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.